NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) has completed the enrollment and dosing of the third cohort of patients diagnosed with advanced, recurrent or progressive cervical cancer in its Phase I/II clinical trial of Lovaxin C. The current assessment by an independent safety panel has found that Lovaxin C, a modified Listeria-based live vaccine is safe, even in end-stage cancer patients, and dose escalation is ongoing.
